Mark T. Reding

2.6k total citations
69 papers, 1.7k citations indexed

About

Mark T. Reding is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Mark T. Reding has authored 69 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Hematology, 13 papers in Genetics and 8 papers in Molecular Biology. Recurrent topics in Mark T. Reding's work include Hemophilia Treatment and Research (51 papers), Platelet Disorders and Treatments (19 papers) and Blood Coagulation and Thrombosis Mechanisms (17 papers). Mark T. Reding is often cited by papers focused on Hemophilia Treatment and Research (51 papers), Platelet Disorders and Treatments (19 papers) and Blood Coagulation and Thrombosis Mechanisms (17 papers). Mark T. Reding collaborates with scholars based in United States, Germany and Italy. Mark T. Reding's co-authors include Bianca M. Conti‐Fine, Brenda Diethelm‐Okita, David K. Okita, Lisa A. Michaels, Nigel S. Key, Anita Shah, Jerry S. Powell, Jennifer Lin, Thomas Coyle and Liana Gercheva and has published in prestigious journals such as Journal of Clinical Investigation, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Mark T. Reding

66 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark T. Reding United States	23	1.4k	305	271	193	170	69	1.7k
Masashi Taki Japan	15	771 0.6×	241 0.8×	160 0.6×	46 0.2×	65 0.4×	58	1.1k
J Cahn France	22	1.2k 0.8×	216 0.7×	282 1.0×	47 0.2×	392 2.3×	70	1.6k
Gregory A. Denomme United States	26	1.7k 1.2×	537 1.8×	159 0.6×	104 0.5×	39 0.2×	110	2.3k
Ralph Cobcroft Australia	14	427 0.3×	126 0.4×	212 0.8×	70 0.4×	231 1.4×	40	857
MW Hilgartner United States	14	1.6k 1.2×	519 1.7×	114 0.4×	121 0.6×	49 0.3×	27	2.0k
Joseph M. Wiley United States	19	630 0.5×	261 0.9×	302 1.1×	39 0.2×	338 2.0×	37	1.5k
Ira Braunschweig United States	19	1.4k 1.0×	283 0.9×	176 0.6×	46 0.2×	642 3.8×	76	2.0k
Mi Kwon Spain	19	547 0.4×	98 0.3×	158 0.6×	57 0.3×	376 2.2×	113	1.1k
Carmen Altisent Spain	21	1.2k 0.9×	315 1.0×	182 0.7×	29 0.2×	43 0.3×	51	1.5k
Deeg Hj United States	15	609 0.4×	126 0.4×	97 0.4×	59 0.3×	208 1.2×	46	893

Countries citing papers authored by Mark T. Reding

Since Specialization

Citations

This map shows the geographic impact of Mark T. Reding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark T. Reding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark T. Reding more than expected).

Fields of papers citing papers by Mark T. Reding

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark T. Reding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark T. Reding. The network helps show where Mark T. Reding may publish in the future.

Co-authorship network of co-authors of Mark T. Reding

This figure shows the co-authorship network connecting the top 25 collaborators of Mark T. Reding. A scholar is included among the top collaborators of Mark T. Reding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark T. Reding. Mark T. Reding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chitlur, Meera, et al.. (2025). Characterization and management of patients with hereditary factor X deficiency: A case series. Transfusion. 65(10). 1786–1792.

Reding, Mark T.. (2025). New therapies in hemophilia: extend the half-life, mimic, or rebalance?. Hematology. 2025(1). 668–673.

Reding, Mark T., Shadan Lalezari, Gili Kenet, et al.. (2024). Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review. Drugs in R&D. 24(3). 359–381. 3 indexed citations

Mahlangu, Johnny, Susan Shapiro, Margareth C. Ozelo, et al.. (2023). Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis. Hämostaseologie. 43(S 01). S96–S96. 1 indexed citations

Reding, Mark T., María Román, Giancarlo Castaman, et al.. (2023). Interim analyses of the multinational real‐world prospective cohort HEM‐POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A. European Journal Of Haematology. 112(2). 286–295. 1 indexed citations

Hermans, Cédric, Mark T. Reding, Jan Astermark, Robert Klamroth, & Maria Elisa Mancuso. (2022). Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspective. Critical Reviews in Oncology/Hematology. 174. 103678–103678. 11 indexed citations

Reding, Mark T., Ingrid Pabinger, Pål André Holme, et al.. (2021). Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study. Haemophilia. 27(3). e347–e356. 15 indexed citations

Kenet, Gili, Yeu‐Chin Chen, Gillian Lowe, et al.. (2021). Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study. Journal of Clinical Medicine. 10(24). 5959–5959. 16 indexed citations

Shah, Surbhi, Nathan D. Shippee, Emma Jones, et al.. (2021). Implementation of an Anticoagulation Practice Guideline for COVID-19 via a Clinical Decision Support System in a Large Academic Health System and Its Evaluation: Observational Study. JMIR Medical Informatics. 9(11). e30743–e30743. 9 indexed citations

10.

Valentino, Leonard A., Judith Baker, Regina B. Butler, et al.. (2021). Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders. Journal of Blood Medicine. Volume 12. 897–911. 27 indexed citations

11.

Lalezari, Shadan, Mark T. Reding, Ingrid Pabinger, et al.. (2019). BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results. Haemophilia. 25(6). 1011–1019. 22 indexed citations

12.

Hegerova, Livia, Qing Cao, John Rogosheske, et al.. (2018). Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 24(12). e20–e25. 11 indexed citations

13.

Kreuziger, Lisa Baumann, Tracy Prosen, & Mark T. Reding. (2013). Use of recombinant human antithrombin concentrate in pregnancy. International Journal of Women s Health. 5. 583–583. 4 indexed citations

14.

Reding, Mark T. & C Cooper. (2012). Barriers to effective diagnosis and management of a bleeding patient with undiagnosed bleeding disorder across multiple specialties: results of a quantitative case-based survey. Journal of Multidisciplinary Healthcare. 5. 277–277. 19 indexed citations

15.

Adams, Julie E. & Mark T. Reding. (2011). Hemophilic Arthropathy of the Elbow. Hand Clinics. 27(2). 151–163. 14 indexed citations

16.

Astermark, Jan, Sébastien Lacroix‐Desmazes, & Mark T. Reding. (2008). Inhibitor Development. Haemophilia. 14(s3). 36–42. 29 indexed citations

17.

Park, Kyong Soo, Angelika C. Gruessner, D. E. R. Sutherland, et al.. (2007). Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. Haematologica. 92(8). 1029–1036. 44 indexed citations

18.

Berntorp, Erik, Jan Astermark, V. Blanchette, et al.. (2006). Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia. 12(s6). 1–7. 82 indexed citations

19.

Reding, Mark T., et al.. (2004). Epitope repertoire of human CD4 T cells on the A3 domain of coagulation factor VIII. Journal of Thrombosis and Haemostasis. 2(8). 1385–1394. 50 indexed citations

20.

Reding, Mark T., et al.. (2003). Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII. Journal of Thrombosis and Haemostasis. 1(8). 1777–1784. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact